NCT05188677View on ClinicalTrials.gov

Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,831

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

June 6, 2023

Study Completion Date

June 6, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

Candidate vaccine, SCB-2019

a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

BIOLOGICAL

Comirnaty Vaccine

intramuscular injection

BIOLOGICAL

Vaxzevria Vaccine

intramuscular injection

BIOLOGICAL

CoronaVac Vaccine

intramuscular injection

Trial Locations (2)

1000

Manila Doctors Hospital, Manila

1741

Las Piñas Doctors Hospital, Las Piñas

Sponsors
All Listed Sponsors
lead

Clover Biopharmaceuticals AUS Pty

INDUSTRY